N/A N=468 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship
Sepsis
Primary: All-cause Mortality and Hospital Readmission Rate — 1023; 684 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=140 Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.
Sepsis, Severe · Septic Shock
Primary: Time to Vasopressor Independence (Hours) — 27; 53 hours — p=<0.001
Phase 4 N=78 Effect of Vitamin D as Adjuvant Therapy in Preterm Infants With Neonatal Sepsis
Neonatal Sepsis · Preterm Infants
Primary: Change From Baseline in the Modified Töllner Sepsis Scoring System After 7 Days — 7; 7; 8; 9 Score — p=<0.001
Phase 3 N=58,747 Azithromycin-Prevention in Labor Use Study (A-PLUS)
Maternal Death · Maternal Infections Affecting Fetus or Newborn · Neonatal SEPSIS
Primary: Maternal Death or Sepsis Within 6 Weeks (42 Days) Post-delivery in Intervention vs. Placebo Group. — 227; 344 Participants — p=<0.001
Phase 3 N=30 Cholecalciferol Supplementation for Sepsis in the ICU
Hypovitaminosis D
Primary: Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol — 19; 15; 17; 19 ng/mL
N/A N=21 Home-based Digital Exercise Training Program to Improve Physical Function of Older Sepsis Survivors - HEAL Sepsis Trial
Exercise Program · Standard Care Control
Primary: Exercise Adherence — 76 Percentage
N/A N=97,507 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates
Neonatal Death · Prematurity
Primary: Use of Parenteral Nutrition (Project A) — 62145 Participants
N/A N=121 Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis
Sepsis
Primary: Antibiotic Treatment for More Than 72 Hours — 33; 55 participants — p=0.002
Phase 4 N=21,832 Neonates and Azithromycin, an Innovation in the Treatment of Children in Burkina Faso
Childhood Mortality
Primary: 6 Month Mortality - All Cause — 42; 50 Participants
Phase 4 N=23 GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
Pediatric Sepsis-induced MODS
Primary: Number of Subjects With Restoration of the TNF-alpha Response — 10; 8 Participants
N/A N=30 A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)
Sepsis
Primary: ICU-free Days to 14 Days After Enrollment — 9; 11 days
N/A N=106,629 Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care
Sepsis
Primary: Door-to-antibiotic Time — 160; 146; 139; 140 minutes — p=<0.001
Phase 2 N=44 Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
N/A N=3,230 Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
Septic Shock · Sepsis
Primary: Time From ED Arrival to Administration of First Dose of Antibiotics — 173; 165; 169; 163 minutes — p=0.29
N/A N=185 Algorithm for Predicting the Unfavorable Course of Sepsis in Children
Sepsis
Primary: Blood Leukocyte Subpopulations: the Absolute Numbers of Leukocytes of Specific Phenotypes — 16.0; 11.2; 11.9; 4.9 10^9 cells/l — p=<0.05